If a product costs thirty times as much as the benefit it brings, and in addition, is capable of releasing a highly toxic chemical, one would not expect that product to be successful. If use of that product is mandated by government regulation, it might succeed in the marketplace despite its shortcomings. The product in question is the refrigerant R1234yf, made by a joint venture of DuPont (DD) and Honeywell (HON), and the prospective customers are auto makers selling in Europe, including Volkswagen (VLKAF.PK), PSA Peugeot (PEUGF.PK), Ford (F), General Motors (GM), Renault (RNSDF.PK), Fiat (FIADF.PK), Toyota (TM), Daimler (DDAIF.PK), and BMW (BAMXF.PK). Will we see a transfer of wealth amounting to hundreds of millions of dollars from these car makers and European car buyers to DD and HON or will the latter two companies have to reduce their earnings expectations?
Folks, no doubt about it. The Kullman Koolant is shaping up as a DUD. Car-makers which persist in loading the grossly expensive, toxic Kullman Koolant into their vehicles may potentially face staggering litigation liability.
Is the Kullman Koolant the DuPont Imprelis of A/C car refrigerants?? Another specimen of DuPont's PR-contrived "world class engineering"?